Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
about
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?The La-Related Proteins, a Family with Connections to CancerTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesTargeting translation initiation in breast cancerStructural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4EeIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognitionTherapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elementsPhosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells.Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E.Targeting the translational machinery as a novel treatment strategy for hematologic malignanciesFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Eukaryotic initiation factor 4F: a vulnerability of tumor cells.Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.When will resistance be futile?Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responsesRegulation of cell growth by Notch signaling and its differential requirement in normal vs. tumor-forming stem cells in DrosophilaRibavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.New sources of drugs for hematologic malignanciesDetection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma.Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.The oncogene eIF4E: using biochemical insights to target cancer.Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancerpeIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas.Proteomic Profiling of Hematopoietic Stem/Progenitor Cells after a Whole Body Exposure of CBA/CaJ Mice to Titanium (48Ti) Ions.Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis.Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cellsPathprinting: An integrative approach to understand the functional basis of disease.PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.
P2860
Q24594939-2AD32AF9-5774-4725-B45C-A053B82FB939Q26778934-6323B36D-F387-4393-8491-D9EFF6900CBFQ26829652-B3ADC8BA-DDBD-4EF8-9F18-0329782C86BDQ27027284-F550F19E-FCD2-49B6-9B0C-DE7393672717Q27660157-7AB80955-E3AA-4D07-996F-ED81B8AEA906Q27676513-7BC2305B-B993-46F9-8C91-57376B7818B9Q28610460-441D6842-FDAA-4C2B-9424-83A2393C587CQ33698105-55100980-9218-45FF-AF34-C0F21ADE2BC6Q33701271-91285F32-E139-442C-A998-B758512A193BQ33708023-7EEB1465-7EF6-486A-B023-B906DACC970FQ33728312-39985225-7CFD-40A6-8209-CECF002570E6Q33747291-CACFCEB2-1B35-411C-AC80-627C57435743Q34105627-BEC7E054-08C7-4C35-8184-82B85F502FD0Q34117251-E3AE2256-7ECE-435D-A222-8469E7083B49Q34173253-65321F6C-98B1-4C33-9B6F-64A9ED424E95Q34240544-717F72EE-65AD-4259-9511-6568CDB50FBAQ34310053-847A35EE-B893-4809-8B78-B58C4F9F4C27Q34545783-483EBB53-07C9-47CB-9A50-62872AF4E26BQ34715457-64C5B57B-1EE6-4522-B6BB-3002DD078E9AQ34917506-410F1D58-8204-47D5-9F16-430DC1E8CE95Q35142765-750E2A2F-9130-459E-A98E-8A9B4955BFC8Q35642076-67D52565-8001-4BF3-9BAD-0C662EB861E7Q35758763-2A8DBC66-971E-44ED-B4B7-36C12AB5F007Q35832407-E23B739C-C2A4-4481-81FA-1B67A59EF9CDQ35979113-7B011C20-3605-445F-BCB8-AA23F367E6BAQ35988511-8CF092BE-44C2-446A-8F5A-D7087305DD93Q36020938-9D99C7A8-2DEE-42FA-BDB6-99B1E43B3EB2Q36390462-365353AF-AC0D-4350-B7C3-404274E33B34Q36596874-891341E4-1290-47ED-8DD5-B76666101B60Q36814636-D4EBC381-59D3-4969-B7D4-217BF7773589Q36842143-3D3887AB-2F99-4932-94F1-DEB7E6A67D9DQ36904927-DADFDD49-D649-4F5C-874E-BFAE46D86FA1Q37117628-23433504-2165-48B6-BB88-606130B3A5FEQ37151073-391A9D98-CB8F-45E8-88F2-05C243334AADQ37321076-7CB61ACA-7EC0-41A9-BA50-04A29BA01F62Q37566468-5E19B860-354E-4DEE-830E-525F76E1D886Q37596308-171F7EFC-FC9F-4365-9CDC-9AA6A25ABBDDQ37636705-6128A54A-DA11-4FA1-A3D3-62AF4891BE4FQ37676855-75A509A3-BA53-4547-AA87-FE5E6796B137Q37688853-B4FE896E-CA7E-4101-9E33-AB9DB2148564
P2860
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Molecular targeting of the onc ...... clinical trial with ribavirin.
@en
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia
@nl
type
label
Molecular targeting of the onc ...... clinical trial with ribavirin.
@en
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia
@nl
prefLabel
Molecular targeting of the onc ...... clinical trial with ribavirin.
@en
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia
@nl
P2093
P1433
P1476
Molecular targeting of the onc ...... clinical trial with ribavirin.
@en
P2093
Abdellatif Amri
Biljana Culjkovic
Brian Leber
Caroline Rousseau
Denis-Claude Roy
Eftihia Cocolakis
Katherine L B Borden
Nathalie Beslu
Sarit Assouline
Stephen Caplan
P304
P356
10.1182/BLOOD-2009-02-205153
P407
P577
2009-05-11T00:00:00Z